Welcome to our dedicated page for Steris Plc news (Ticker: STE), a resource for investors and traders seeking the latest updates and insights on Steris Plc stock.
Steris Plc (STE) is a global leader in medical sterilization and infection prevention solutions, serving healthcare, pharmaceutical, and life sciences industries. This news hub provides investors and professionals with timely updates on corporate developments shaping the critical field of healthcare safety.
Access consolidated Steris news including earnings reports, regulatory milestones, product innovations, and strategic partnerships. Our verified updates ensure you stay informed about developments impacting infection control technologies and medical equipment sterilization services.
Key content focuses on financial performance updates, FDA clearances for sterilization systems, contract service expansions, and R&D breakthroughs in decontamination science. All materials are sourced directly from company filings and authorized communications.
Bookmark this page for streamlined access to Steris' official announcements. Check regularly for updates on operational developments affecting healthcare providers and medical device manufacturers worldwide.
STERIS plc (NYSE: STE) announced a significant leadership transition as long-time Chief Financial Officer Michael J. Tokich steps down after 17 years in the role. Karen L. Burton, currently Vice President and Chief Accounting Officer, will succeed Tokich as Senior Vice President and CFO effective August 18, 2025.
Under Tokich's tenure as CFO since 2008, STERIS has experienced remarkable growth, with revenue quadrupling and market capitalization increasing from $1 billion to $22 billion. Tokich will transition to the role of Senior Financial Advisor, reporting to the CEO. Burton, who has been with STERIS since 2004 and served as CAO since 2017, will oversee all global finance functions and IT in her new role.
STERIS plc (NYSE: STE) reported strong fiscal 2026 first quarter results, with total revenue increasing 9% to $1.4 billion and constant currency organic revenue growing 8%. The company's net income from continuing operations reached $177.4 million, or $1.79 per diluted share, while adjusted EPS grew to $2.34.
Performance was driven by growth across all segments: Healthcare revenue grew 8% to $974.7 million, Applied Sterilization Technologies increased 13% to $281.2 million, and Life Sciences rose 5% to $135.2 million. Free cash flow significantly improved to $326.5 million.
STERIS updated its fiscal 2026 outlook, raising revenue growth expectations to 8-9% from 6-7%, while maintaining adjusted EPS guidance of $9.90-$10.15. The company now expects free cash flow of approximately $820 million, up from previous guidance of $770 million.
STERIS (NYSE: STE) has announced a quarterly dividend increase to $0.63 per share, marking a $0.06 increase from the previous dividend. This represents the company's 20th consecutive year of dividend growth. The dividend will be payable on September 26, 2025, to shareholders of record as of September 4, 2025.
STERIS, a leading global provider of products and services supporting patient care with a focus on infection prevention, continues to demonstrate its commitment to shareholder returns through consistent dividend growth. The company helps create a healthier and safer world by providing innovative healthcare and life science solutions globally.
STERIS (NYSE: STE) has scheduled a conference call to discuss its fiscal 2026 first quarter results on August 7, 2025, at 9:00 a.m. ET. The company will release its financial results after market close on August 6, 2025.
Investors can access the call through www.steris-ir.com or by phone using specific dial-in numbers for U.S. (1-833-535-2199) and international (1-412-902-6776) participants. A replay will be available from 12:00 p.m. ET on August 7, using access code 2889488.
STERIS (NYSE: STE) reported strong financial results for fiscal 2025, with full-year revenue from continuing operations increasing 6% to $5.5 billion. The company's fourth quarter revenue grew 4% to $1.5 billion, with constant currency organic revenue growth of 6%. Full-year net income reached $610.1 million, or $6.16 per diluted share, while adjusted EPS increased to $9.22.
Healthcare segment revenue grew 5% to $1.1 billion in Q4, while Applied Sterilization Technologies (AST) revenue increased 9% to $273.9 million. Life Sciences revenue decreased 7% to $149.5 million. The company generated strong free cash flow of $787.2 million for fiscal 2025.
For fiscal 2026, STERIS expects 6-7% revenue growth and adjusted EPS of $9.90-$10.15, despite an estimated $30 million negative impact from tariffs.
STERIS (NYSE: STE) has announced it will host a conference call on May 15, 2025 at 9:00 a.m. ET to discuss its fiscal 2025 fourth quarter and full year financial results. The company will release its financial results press release after market close on May 14, 2025.
Investors can access the live call through www.steris-ir.com or by phone using 1-833-535-2199 (US) or 1-412-902-6776 (International). A replay will be available from 12:00 p.m. ET on May 15, using access code 5194825, via the company website or by calling 1-877-344-7529 (US) or 1-412-317-0088 (International).
STERIS (NYSE: STE) reported strong financial results for Q3 FY2025. Total revenue from continuing operations increased 6% to $1.4 billion, with constant currency organic revenue also growing 6%. Net income reached $173.6 million ($1.75 per diluted share), up from $148.4 million in Q3 FY2024. Adjusted net income was $229.1 million ($2.32 per diluted share).
Healthcare revenue grew 7% to $976.0 million, while Applied Sterilization Technologies revenue increased 10% to $258.1 million. Life Sciences revenue decreased 7% to $136.4 million. Free cash flow for the first nine months reached $588.1 million, up from $457.0 million.
The company updated its FY2025 outlook, now expecting revenue growth of approximately 6%, down from previous guidance of 6.5-7.5%, primarily due to currency impacts and lower Healthcare capital equipment revenue. Adjusted EPS guidance was revised to $9.05-$9.15.
STERIS plc (NYSE: STE) has announced a quarterly interim dividend of $0.57 per share. The dividend will be paid on March 21, 2025, to shareholders who are on record at the close of business on February 20, 2025.
STERIS, a leading global provider of products and services focused on infection prevention, supports patient care and helps customers create a healthier and safer world through innovative healthcare and life sciences solutions globally.
STERIS (NYSE: STE) has announced it will host a conference call on February 6, 2025, at 9:00 a.m. ET to discuss its fiscal 2025 third quarter financial results. The company will release its financial results press release after U.S. market closure on February 5, 2025.
Investors can access the live conference call through www.steris-ir.com or by phone using 1-833-535-2199 (U.S.) or 1-412-902-6776 (International). A replay will be available from 12:00 p.m. ET on February 6, using access code 2513153, accessible via the company website or by calling 1-877-344-7529 (U.S.) or 1-412-317-0088 (International).
FAQ
What is the current stock price of Steris Plc (STE)?
What is the market cap of Steris Plc (STE)?
